Aminocaproic acid

Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Treatment and prophylaxis of haemorrhage due to hyperfibrinolysis Initial: 4-5 g, followed by 1-1.25 g hrly for up to 8 hr. Max: 24 g/day. Patients w/ haemophilia undergoing dental extraction 50-100 mg/kg 4-6 hrly started before the procedure up to 7-10 days. Max: 24 g/day. IV Treatment and prophylaxis of haemorrhage due to hyperfibrinolysis As 2% soln: Initial: 4-5 g over 1 hr, followed by continuous infusion of 1 g/hr for up to 8 hr. Max: 24 g/day.
May be taken with or without food. May be taken w/ meals to prevent GI upset.
Active intravascular clotting process, disseminated intravascular coagulation (w/o heparin). Concomitant use w/ factor IX complex and anti-inhibitor coagulant complex.
Special Precautions
Patient w/ cardiac disease, haematuria of upper urinary tract, uraemia. Admin by rapid IV inj of undiluted soln. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor creatine phosphokinase (CPK) for signs of muscle damage esp in patients receiving long-term therapy. Monitor for fibrinogen, fibrin split products, BUN, and creatinine.
Adverse Reactions
Headache, oedema, tinnitus, nasal and conjunctival congestion, malaise; anaphylaxis, rash; thrombosis; hypotension, bradycardia, peripheral ischaemia; abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leucopenia, thrombocytopenia; increased CPK, muscle weakness, myalgia, myopathy, myositis, rhabdomyolysis; increase BUN, confusion, convulsions, delirium, dizziness, hallucinations, intracranial HTN, stroke, syncope, dyspnoea, pulmonary embolism, pruritus; decreased vision, watery eyes, cardiac and hepatic damage, renal failure.
Drug Interactions
Enhanced thrombogenic effect w/ oral tretinoin. May increase risk of thrombosis w/ fibrinogen concentrate.
CIMS Class
ATC Classification
B02AA01 - aminocaproic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Disclaimer: This information is independently developed by CIMS based on aminocaproic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in